貝瑞基因(000710.SZ)一季度淨利潤預降52%-68%
格隆匯 4 月 14日丨貝瑞基因(000710.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤2000萬元-3000萬元,同比下降52%-68%;扣除非經常性損益後的淨利潤2000萬元-3000萬元,同比下降51%-67%。業績變動原因如下:
1、後疫情階段醫院診療人數恢復較慢,佔公司營業收入較大的醫學產品及服務有待恢復,導致公司整體營業收入減少。出生人口數量持續下降背景下,佔公司醫學產品及服務較大的NIPT檢測數量增速放緩,且檢測價格下降,導致公司整體營業毛利率降低。
2、報吿期,公司優化銷售體系、增加研發投入,不斷豐富業務儲備。公司激勵團隊,持續推進基因測序技術在臨牀應用的轉化,聚焦主業、踐行戰略,實現公司業績持續增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.